
## Chung SM, et a

EnM



**Supplemental Fig. S1.** Patient selection flowchart. FIB-4, fibrosis-4; LSM, liver stiffness measurement. <sup>a</sup>Abdominal obesity, elevated triglyceride, reduced high-density lipoprotein cholesterol, elevated blood pressure, and elevated fasting glucose (impaired fasting glucose or type 2 diabetes); <sup>b</sup>Diagnosed with ultrasound (increased echogenicity of the liver parenchyma relative to that of the cortex of the kidneys, unclear visualization of the intrahepatic vessels, and/or deep beam attenuation) or transient elastography (TE) (FibroScan; controlled attenuation parameter  $\geq$  248 dB/m). TE was performed in all participants; <sup>c</sup>Liver biopsy was performed if the patented serum tests (cutoffs to use: enhanced liver fibrosis 9.8; FibroMeter 0.45, Fibrotest 0.48) were discordant with LSM.